Author:
Fadeev R. S.,Dolgikh N. V.,Chekanov A. V.,Senotov A. S.,Krasnov K. S.,Kobyakova M. I.,Lomovskaya Ya. V.,Fadeeva I. S.,Akatov V. S.
Subject
Cell Biology,Biochemistry,Biophysics
Reference19 articles.
1. Chamuleau M.E., Ossenkoppele G.J., van Rhenen A., van Dreunen, L., Jirka S.M., Zevenbergen A., Schuurhuis G.J., van de Loosdrecht A.A. 2011. High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. Leuk. Res.
35, 741–749.
2. Cheng J., Hylander B.L., Baer M.R., Chen X., Repasky E.A. 2006. Multiple mechanisms underlie resistance of leukemia cells to Apo2 Ligand/TRAIL. Mol. Cancer Ther.
5, 1844–1853.
3. Riccioni R., Pasquini L., Mariani G., Saulle E., Rossini A., Diverio D., Pelosi E., Vitale A., Chierichini A., Cedrone M., Foa R., Coco F., Peschle C., Testa U. 2005. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica. 90, 612–624.
4. Buchsbaum D.J., Zhou T., Lobuglio A.F. 2006.TRAIL receptor-targeted therapy. Future Oncol.
2, 493–508.
5. Zhang L., Fang B. 2005. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Therapy.
12, 228–237.